{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:02:32Z","timestamp":1794052952690,"version":"4.8.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018234","name":"Inselspital, Universit\u00e4tsspital Bern","doi-asserted-by":"publisher","award":["Protected Research Time"],"award-info":[{"award-number":["Protected Research Time"]}],"id":[{"id":"10.13039\/100018234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009068","name":"University of Bern","doi-asserted-by":"publisher","award":["Protected Research Time"],"award-info":[{"award-number":["Protected Research Time"]}],"id":[{"id":"10.13039\/100009068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PZ00P3_201672\/1"],"award-info":[{"award-number":["PZ00P3_201672\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypophosphatemia, defined as low serum phosphate levels, is a frequent yet underrecognized condition associated with significant morbidity. Its etiology ranges from chronic conditions such as osteomalacia to acute states such as refeeding syndrome. This review systematically summarizes evidence and guidelines for phosphate testing and supplementation in adults, aiming to support clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review following the PRISMA guidelines. Searches of MEDLINE, Embase, the Cochrane Library, and Google Scholar from inception to September 2024 included reviews, guidelines, and consensus statements addressing phosphate measurement for hypophosphatemia and supplementation in adults outside intensive care settings. Eligibility criteria included English-language publications focused on diagnostic and therapeutic recommendations. Quality assessment was performed using the AGREE II tool, and data were synthesized across chronic and acute clinical contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-three publications (11 guidelines, 19 reviews, and 3 consensus statements) were included, with high heterogeneity in the recommendations. Phosphate measurement to evaluate chronic hypophosphatemia is recommended for persistent musculoskeletal symptoms, osteoporosis evaluation, and rare conditions known to cause chronic hypophosphatemia, such as X-linked hypophosphatemia and tumor-induced osteomalacia. The post-kidney transplantation stage requires intensive early monitoring for hypophosphatemia. Recommendations for testing for drug-induced hypophosphatemia, such as with ferric carboxymaltose, vary. Phosphate measurement to evaluate acute hypophosphatemia is advised in high-risk settings: refeeding syndrome, hyperglycemic hyperosmolar syndrome, alcoholic ketoacidosis, worsening COPD or asthma exacerbations. Further potential indications for phosphate measurement include certain iron infusions, tenofovir treatment, immediate post-kidney transplantation, and intensive hemodialysis. Supplementation is indicated for severe or symptomatic cases, with oral therapy preferred for chronic conditions and intravenous routes for acute, severe hypophosphatemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The heterogeneity in the recommendations emphasizes the need for individualized approaches based on clinical context. While robust evidence supports testing and supplementation under select conditions, gaps remain regarding optimal dosing and monitoring protocols. Clinicians should consider phosphate testing in high-risk scenarios and follow evidence-based supplementation guidelines tailored to chronic and acute hypophosphatemia. Future research is needed to unify recommendations and address existing uncertainties.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04415-1","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:08:33Z","timestamp":1761570513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Indications for the evaluation and supplementation of hypophosphatemia: an umbrella systematic review of reviews and guidelines"],"prefix":"10.1186","volume":"23","author":[{"given":"Seraina","family":"Netzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"B\u00fcchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina E.","family":"B\u00fcchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole E.","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"4415_CR1","unstructured":"Sharma S, Hashmi MF, Castro D. Hypophosphatemia. In StatPearls. Treasure Island: StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK493172\/."},{"issue":"7","key":"4415_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1759720X18779761","volume":"10","author":"AL Day","year":"2018","unstructured":"Day AL, Morgan SL, Saag KG. Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm. Ther Adv Musculoskelet Dis. 2018;10(7):151\u20136.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"4415_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1053\/j.ajkd.2012.03.024","volume":"60","author":"AJ Felsenfeld","year":"2012","unstructured":"Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis. 2012;60(4):655\u201361.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"4415_CR4","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ncp.10474","volume":"35","author":"JSV da Silva","year":"2020","unstructured":"da Silva JSV, Seres DS, Sabino K, Adams SC, Berdahl GJ, Citty SW, et al. ASPEN consensus recommendations for refeeding syndrome. Nutr Clin Pract. 2020;35(2):178\u201395.","journal-title":"Nutr Clin Pract"},{"issue":"3","key":"4415_CR5","first-page":"136","volume":"2","author":"J Amanzadeh","year":"2006","unstructured":"Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat. 2006;2(3):136\u201348.","journal-title":"Nat"},{"issue":"10","key":"4415_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s40618-018-0849-5","volume":"41","author":"JM Boland","year":"2018","unstructured":"Boland JM, Tebben PJ, Folpe AL. Phosphaturic mesenchymal tumors: what an endocrinologist should know. J Endocrinol Invest. 2018;41(10):1173\u201384.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"4415_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-019-00888-1","volume":"43","author":"E Megapanou","year":"2020","unstructured":"Megapanou E, Florentin M, Milionis H, Elisaf M, Liamis G. Drug-induced hypophosphatemia: current insights. Drug Saf. 2020;43(3):197\u2013210.","journal-title":"Drug Saf"},{"issue":"10","key":"4415_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40264-022-01216-w","volume":"45","author":"JMM Boots","year":"2022","unstructured":"Boots JMM, Quax RAM. High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: a benefit-risk assessment. Drug Saf. 2022;45(10):1019\u201336.","journal-title":"Drug Saf"},{"issue":"8","key":"4415_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1507\/endocrj.EJ15-0289","volume":"62","author":"S Fukumoto","year":"2015","unstructured":"Fukumoto S, Ozono K, Michigami T, Minagawa M, Okazaki R, Sugimoto T, et al. Pathogenesis and diagnostic criteria for rickets and osteomalacia -proposal by an expert panel supported by ministry of health, Labour and Welfare, Japan, the Japanese society for bone and mineral research and the Japan endocrine society. Endocr J. 2015;62(8):665\u201371.","journal-title":"Endocr J"},{"issue":"2","key":"4415_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.emc.2013.12.006","volume":"32","author":"WTW Chang","year":"2014","unstructured":"Chang WTW, Radin B, McCurdy MT. Calcium, magnesium, and phosphate abnormalities in the emergency department. Emerg Med Clin North Am. 2014;32(2):349\u201366.","journal-title":"Emerg Med Clin North Am"},{"key":"4415_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"12","key":"4415_CR12","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jclinepi.2010.07.001","volume":"63","author":"MC Brouwers","year":"2010","unstructured":"Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Agree II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63(12):1308\u201311.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"4415_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435\u201355.","journal-title":"Nat Rev Nephrol"},{"key":"4415_CR14","doi-asserted-by":"crossref","unstructured":"Jan de Beur SM, Minisola S, Xia WB, Abrahamsen B, Body JJ, Brandi ML, et al. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med. 2023;293(3):309\u201328.","DOI":"10.1111\/joim.13593"},{"key":"4415_CR15","doi-asserted-by":"crossref","unstructured":"Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, et al. Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: A consensus statement from the FD\/MAS international consortium. Orphanet Journal of Rare Diseases. 2019;14(1) (no pagination).","DOI":"10.1186\/s13023-019-1102-9"},{"issue":"1","key":"4415_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes CKDMBDUWG","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes CKDMBDUWG. Kdigo 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1\u201359.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"4415_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17(1):58.","journal-title":"Arch Osteoporos"},{"issue":"11","key":"4415_CR18","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jbmr.4677","volume":"37","author":"JP Bilezikian","year":"2022","unstructured":"Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international Workshop. J Bone Miner Res. 2022;37(11):2293\u2013314.","journal-title":"J Bone Miner Res"},{"key":"4415_CR19","unstructured":"National Institute for Health and Care Excellence (NICE). Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. NICE Clinical Guideline CG32. London: NICE; 2006 [updated August 2017]. Available from: https:\/\/www.nice.org.uk\/guidance\/cg32\/resources\/cg32-nutrition-support-in-adults-full-guideline."},{"issue":"1","key":"4415_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.ajkd.2013.02.351","volume":"62","author":"GE Nesrallah","year":"2013","unstructured":"Nesrallah GE, Mustafa RA, Macrae J, Pauly RP, Perkins DN, Gangji A, et al. Canadian society of nephrology guidelines for the management of patients with ESRD treated with intensive hemodialysis. Am J Kidney Dis. 2013;62(1):187\u201398.","journal-title":"Am J Kidney Dis"},{"key":"4415_CR21","unstructured":"European AIDS Clinical Society (EACS). Guidelines Version 12.0. October 2023. European AIDS Clinical Society. EACS Guidelines Version 12.0. Brussels: EACS; 2023. Available from: https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf."},{"key":"4415_CR22","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services; 2024. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"4415_CR23","volume":"18","author":"SA Ackah","year":"2022","unstructured":"Ackah SA, Imel EA. Approach to hypophosphatemic rickets. J Clin Endocrinol Metab. 2022;18:18.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4415_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jbmr.4486","volume":"37","author":"F Aljuraibah","year":"2022","unstructured":"Aljuraibah F, Bacchetta J, Brandi ML, Florenzano P, Javaid MK, Makitie O, et al. An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia. J Bone Miner Res. 2022;37(1):12\u201320.","journal-title":"J Bone Miner Res"},{"key":"4415_CR25","doi-asserted-by":"crossref","unstructured":"Baia LC, Heilberg IP, Navis G, de Borst MH, investigators N. Phosphate and FGF-23 homeostasis after kidney transplantation. Nat Rev Nephrol. 2015;11(11):656\u201366.","DOI":"10.1038\/nrneph.2015.153"},{"issue":"2","key":"4415_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101844","volume":"38","author":"KE Cherian","year":"2024","unstructured":"Cherian KE, Paul TV. Inherited fibroblast growth factor 23 excess. Best Pract Res Clin Endocrinol Metab. 2024;38(2):101844.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"4415_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S2213-8587(19)30426-7","volume":"8","author":"P Florenzano","year":"2020","unstructured":"Florenzano P, Cipriani C, Roszko KL, Fukumoto S, Collins MT, Minisola S, et al. Approach to patients with hypophosphataemia. Lancet Diabetes Endocrinol. 2020;8(2):163\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4415_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2147\/DMSO.S50516","volume":"7","author":"AR Gosmanov","year":"2014","unstructured":"Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014;7:255\u201364.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"4415_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/0884533614565251","volume":"30","author":"MD Kraft","year":"2015","unstructured":"Kraft MD. Phosphorus and calcium: a review for the adult nutrition support clinician. Nutr Clin Pract. 2015;30(1):21\u201333.","journal-title":"Nutr Clin Pract"},{"issue":"1","key":"4415_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.13659","volume":"44","author":"P Lampertico","year":"2016","unstructured":"Lampertico P, Chan HLY, Janssen HLA, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44(1):16\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"4415_CR31","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jemermed.2021.09.007","volume":"61","author":"B Long","year":"2021","unstructured":"Long B, Lentz S, Gottlieb M. Alcoholic ketoacidosis: etiologies, evaluation, and management. J Emerg Med. 2021;61(6):658\u201365.","journal-title":"J Emerg Med"},{"issue":"11","key":"4415_CR32","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1517\/14656566.6.11.1841","volume":"6","author":"HJ Milionis","year":"2005","unstructured":"Milionis HJ, Elisaf MS. Therapeutic management of hyperglycaemic hyperosmolar syndrome. Expert Opin Pharmacother. 2005;6(11):1841\u20139.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"4415_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/ajem.2000.7347","volume":"18","author":"DW Miller","year":"2000","unstructured":"Miller DW, Slovis CM. Hypophosphatemia in the emergency department therapeutics. Am J Emerg Med. 2000;18(4):457\u201361.","journal-title":"Am J Emerg Med"},{"key":"4415_CR34","doi-asserted-by":"publisher","unstructured":"Reber E, Friedli N, Vasiloglou MF, Schuetz P, Stanga Z. Management of refeeding syndrome in medical inpatients. J Clin Med. 2019;8(12):2202. https:\/\/doi.org\/10.3390\/jcm8122202.","DOI":"10.3390\/jcm8122202"},{"issue":"5","key":"4415_CR35","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/CAD.0b013e32833760bf","volume":"21","author":"J Rodriguez-Pascual","year":"2010","unstructured":"Rodriguez-Pascual J, Cheng E, Maroto P, Duran I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs. 2010;21(5):478\u201386.","journal-title":"Anticancer Drugs"},{"key":"4415_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116202","volume":"154","author":"B Schaefer","year":"2022","unstructured":"Schaefer B, Tobiasch M, Wagner S, Glodny B, Tilg H, Wolf M, et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2022;154:116202.","journal-title":"Bone"},{"key":"4415_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00211","volume":"5","author":"C Vangala","year":"2018","unstructured":"Vangala C, Pan J, Cotton RT, Ramanathan V. Mineral and bone disorders after kidney transplantation. Front Med Lausanne. 2018;5:211.","journal-title":"Front Med Lausanne"},{"issue":"6","key":"4415_CR38","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jbmr.4558","volume":"37","author":"T Vilaca","year":"2022","unstructured":"Vilaca T, Velmurugan N, Smith C, Abrahamsen B, Eastell R. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports. J Bone Miner Res. 2022;37(6):1188\u201399.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"4415_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40610-019-0118-1","volume":"5","author":"TJ Weber","year":"2019","unstructured":"Weber TJ, Quarles LD. Molecular control of phosphorus homeostasis and precision treatment of hypophosphatemic disorders. Curr Mol Biol Rep. 2019;5(2):75\u201385.","journal-title":"Curr Mol Biol Rep"},{"issue":"1","key":"4415_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1542-4758.2006.01170.x","volume":"10","author":"R Sam","year":"2006","unstructured":"Sam R, Vaseemuddin M, Leong WH, Rogers BE, Kjellstrand CM, Ing TS. Composition and clinical use of hemodialysis. Hemodial Int. 2006;10(1):15\u201328.","journal-title":"Hemodial Int"},{"issue":"6","key":"4415_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti A, Al-Daghri N, Brandi ML, Cannata-Andia JB, Cavalier E, Chandran M, et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol. 2022;18(6):366\u201384.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"4415_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1507\/endocrj.K08E-076","volume":"55","author":"S Fukumoto","year":"2008","unstructured":"Fukumoto S, Namba N, Ozono K, Yamauchi M, Sugimoto T, Michigami T, et al. Causes and differential diagnosis of hypocalcemia - recommendation proposed by expert panel supported by ministry of health, labour and welfare, Japan. Endocr J. 2008;55(5):787\u201394.","journal-title":"Endocr J"},{"key":"4415_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072714","author":"L Arboleya","year":"2023","unstructured":"Arboleya L, Brana I, Pardo E, Loredo M, Queiro R. Osteomalacia in adults: a practical insight for clinicians. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12072714.","journal-title":"J Clin Med"},{"issue":"1","key":"4415_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","volume":"108","author":"P Florenzano","year":"2021","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tissue Int. 2021;108(1):128\u201342.","journal-title":"Calcif Tissue Int"},{"key":"4415_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116064","volume":"152","author":"ML Brandi","year":"2021","unstructured":"Brandi ML, Clunie GPR, Houillier P, de Jan Beur SM, Minisola S, Oheim R, et al. Challenges in the management of tumor-induced osteomalacia (TIO). Bone. 2021;152:116064.","journal-title":"Bone"},{"issue":"5","key":"4415_CR46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update executive summary. Endocr Pract. 2020;26(5):564\u201370.","journal-title":"Endocr Pract"},{"issue":"4","key":"4415_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1053\/j.ajkd.2014.04.028","volume":"64","author":"AR Chang","year":"2014","unstructured":"Chang AR, Grams ME. Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting. Am J Kidney Dis. 2014;64(4):567\u201373.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"4415_CR48","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1210\/clinem\/dgae290","volume":"109","author":"MB Demay","year":"2024","unstructured":"Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"4415_CR49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jsbmb.2017.01.021","volume":"175","author":"P Pludowski","year":"2018","unstructured":"Pludowski P, Holick MF, Grant WB, Konstantynowicz J, Mascarenhas MR, Haq A, et al. Vitamin D supplementation guidelines. J Steroid Biochem Mol Biol. 2018;175:125\u201335.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"4415_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-009307","author":"N Suarez","year":"2013","unstructured":"Suarez N, Conway N, Pickett T. Panic-related hyperventilation resulting in hypophosphataemia and a high lactate. BMJ Case Rep. 2013. https:\/\/doi.org\/10.1136\/bcr-2013-009307.","journal-title":"BMJ Case Rep"},{"issue":"1","key":"4415_CR51","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1210\/jcem-57-1-177","volume":"57","author":"JN Fisher","year":"1983","unstructured":"Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab. 1983;57(1):177\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"4415_CR52","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0002-9343(79)90751-4","volume":"67","author":"RJ Winter","year":"1979","unstructured":"Winter RJ, Harris CJ, Phillips LS, Green OC. Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. Am J Med. 1979;67(5):897\u2013900.","journal-title":"Am J Med"},{"issue":"4","key":"4415_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5005\/jp-journals-10071-24431","volume":"27","author":"A Bsar","year":"2023","unstructured":"Bsar A, El-Wakiel SA, El-Harrisi MA, Elshafei ASH. Frequency and risk factors of hypophosphatemia in patients admitted to emergency intensive care unit in Zagazig University hospitals. Indian J Crit Care Med. 2023;27(4):277\u201382.","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"4415_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-200001000-00001","volume":"79","author":"R Subramanian","year":"2000","unstructured":"Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). 2000;79(1):1\u20138.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"4415_CR55","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793\u2013803.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"4415_CR56","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","volume":"107","author":"B Schaefer","year":"2022","unstructured":"Schaefer B, Zoller H, Wolf M. Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. J Clin Endocrinol Metab. 2022;107(4):1009\u201319.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"4415_CR57","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","volume":"72","author":"H Zoller","year":"2023","unstructured":"Zoller H, Wolf M, Blumenstein I, Primas C, Lindgren S, Thomsen LL, et al. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial. Gut. 2023;72(4):644\u201353.","journal-title":"Gut"},{"key":"4415_CR58","unstructured":"FDA. Injectafer (ferric carboxymaltose injection) 2024 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/203565s027lbl.pdf."},{"key":"4415_CR59","unstructured":"EMA. Ferric Carboxymaltose Summary of Product Characteristics 2024 [Available from: https:\/\/www.medicines.org.uk\/emc\/product\/5910\/smpc."},{"issue":"1","key":"4415_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1071\/SH10021","volume":"8","author":"R Foster","year":"2011","unstructured":"Foster R, Morris S, Ryder N, Wray L, McNulty A. Screening of HIV-infected patients for non-AIDS-related morbidity: an evidence-based model of practice. Sex Health. 2011;8(1):30\u201342.","journal-title":"Sex Health"},{"issue":"4","key":"4415_CR61","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/135965350901400404","volume":"14","author":"CI Bagnis","year":"2009","unstructured":"Bagnis CI, Karie S, Deray G, Essig M. Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients. Antivir Ther. 2009;14(4):481\u20138.","journal-title":"Antivir Ther"},{"issue":"8","key":"4415_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1056\/NEJM196802222780802","volume":"278","author":"M Lotz","year":"1968","unstructured":"Lotz M, Zisman E, Bartter FC. Evidence for a phosphorus-depletion syndrome in man. N Engl J Med. 1968;278(8):409\u201315.","journal-title":"N Engl J Med"},{"issue":"3","key":"4415_CR63","doi-asserted-by":"publisher","first-page":"R247","DOI":"10.1530\/ERC-12-0400","volume":"21","author":"JO Aleman","year":"2014","unstructured":"Aleman JO, Farooki A, Girotra M. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer. 2014;21(3):R247-59.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"4415_CR64","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.leukres.2013.01.021","volume":"37","author":"M Breccia","year":"2013","unstructured":"Breccia M, Alimena G. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leuk Res. 2013;37(6):713\u201320.","journal-title":"Leuk Res"},{"issue":"4","key":"4415_CR65","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/annonc\/mdr010","volume":"22","author":"E Bellini","year":"2011","unstructured":"Bellini E, Pia A, Brizzi MP, Tampellini M, Torta M, Terzolo M, et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol. 2011;22(4):988\u201390.","journal-title":"Ann Oncol"},{"issue":"1","key":"4415_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1399-6576.2010.02338.x","volume":"55","author":"M Broman","year":"2011","unstructured":"Broman M, Carlsson O, Friberg H, Wieslander A, Godaly G. Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. Acta Anaesthesiol Scand. 2011;55(1):39\u201345.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"4415_CR67","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1046\/j.1523-1755.2001.00755.x","volume":"59","author":"M Levi","year":"2001","unstructured":"Levi M. Post-transplant hypophosphatemia. Kidney Int. 2001;59(6):2377\u201387.","journal-title":"Kidney Int"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04415-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04415-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:03:18Z","timestamp":1761573798000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04415-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4415"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04415-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"591"}}